539 related articles for article (PubMed ID: 10416595)
21. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
[TBL] [Abstract][Full Text] [Related]
22. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas.
Takahashi M; Ozaki T; Todo S; Nakagawara A
Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504
[TBL] [Abstract][Full Text] [Related]
23. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas.
Leone A; Seeger RC; Hong CM; Hu YY; Arboleda MJ; Brodeur GM; Stram D; Slamon DJ; Steeg PS
Oncogene; 1993 Apr; 8(4):855-65. PubMed ID: 8384356
[TBL] [Abstract][Full Text] [Related]
24. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)].
Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M
Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442
[TBL] [Abstract][Full Text] [Related]
25. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
[TBL] [Abstract][Full Text] [Related]
26. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G
Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847
[TBL] [Abstract][Full Text] [Related]
27. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation.
Gross N; Beretta C; Peruisseau G; Jackson D; Simmons D; Beck D
Cancer Res; 1994 Aug; 54(15):4238-42. PubMed ID: 7518353
[TBL] [Abstract][Full Text] [Related]
28. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.
Nakagawara A; Arima-Nakagawara M; Scavarda NJ; Azar CG; Cantor AB; Brodeur GM
N Engl J Med; 1993 Mar; 328(12):847-54. PubMed ID: 8441429
[TBL] [Abstract][Full Text] [Related]
29. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
30. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma.
Amler LC; Schürmann J; Schwab M
Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178
[TBL] [Abstract][Full Text] [Related]
31. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
[TBL] [Abstract][Full Text] [Related]
33. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma.
Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M
Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322
[TBL] [Abstract][Full Text] [Related]
34. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
Gehring M; Berthold F; Edler L; Schwab M; Amler LC
Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
[TBL] [Abstract][Full Text] [Related]
35. myc gene amplification and expression in primary human neuroblastoma.
Slavc I; Ellenbogen R; Jung WH; Vawter GF; Kretschmar C; Grier H; Korf BR
Cancer Res; 1990 Mar; 50(5):1459-63. PubMed ID: 2302711
[TBL] [Abstract][Full Text] [Related]
36. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
37. N-myc amplification and cell proliferation rate in human neuroblastoma.
Pession A; Trerè D; Perri P; Rondelli R; Montanaro L; Mantovani W; Derenzini M; Paolucci G
J Pathol; 1997 Nov; 183(3):339-44. PubMed ID: 9422991
[TBL] [Abstract][Full Text] [Related]
38. Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.
Poremba C; Hero B; Goertz HG; Scheel C; Wai D; Schaefer KL; Christiansen H; Berthold F; Juergens H; Boecker W; Dockhorn-Dworniczak B
Klin Padiatr; 2001; 213(4):186-90. PubMed ID: 11528552
[TBL] [Abstract][Full Text] [Related]
39. Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features.
Ball NS; King PH
Clin Cancer Res; 1997 Oct; 3(10):1859-65. PubMed ID: 9815574
[TBL] [Abstract][Full Text] [Related]
40. Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation.
Tsuda H; Shimosato Y; Upton MP; Yokota J; Terada M; Ohira M; Sugimura T; Hirohashi S
Lab Invest; 1988 Sep; 59(3):321-7. PubMed ID: 3411933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]